*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Atlanta, GA | Posted: September 18, 2017
Summary Sentence:
Associate Professor Aaron Levine delivered an important presentation in Boston last week.
Full Summary:
No summary paragraph submitted.
Aaron LevineAaron Levine, Associate Professor in the School of Public Policy, gave an invited presentation on ethical considerations in the translation of CAR-T cell therapies at the 3rd annual CAR-TCR Summit in Boston in early September.
The conference came at an exciting time for oncology, just a week after the historic FDA approval of the first CAR-T therapy in which a patient’s immune cells are removed from their body, genetically engineered to attack specific cancer cells and then infused back to the patient. Dr. Levine addressed the ethical challenges associated with bringing these powerful but highly toxic therapies to market and identified pitfalls to watch for and strategies to use to help the field develop ethically and efficiently.
